LEADER 01750oam  2200469   450 
001 9910709638203321
005 20181107143110.0
035   $a(CKB)5470000002471856
035   $a(OCoLC)1039079947
035   $a(EXLCZ)995470000002471856
100   $a20180607d2018      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAssessing VA's risks for drug diversion $ehearing before the Subcommittee on Oversight and Investigations of the Committee on Veterans' Affairs, U.S. House of Representatives, One Hundred Fifteenth Congress, first session, Monday, February 27, 2017
210  1$aWashington :$cU.S. Government Publishing Office,$d2018.
215   $a1 online resource (iii, 41 pages)
300   $a"Serial no. 115-4."
320   $aIncludes bibliographical references.
517   $aAssessing VA's risks for drug diversion 
606   $aHospital pharmacies$xSecurity measures$zUnited States$xEvaluation
606   $aVeterans' hospitals$xSecurity measures$zUnited States$xEvaluation
606   $aOpioid abuse$zUnited States
606   $aDrugs$xPrescribing$xCorrupt practices$zUnited States
608   $aLegislative hearings.$2lcgft
615  0$aHospital pharmacies$xSecurity measures$xEvaluation.
615  0$aVeterans' hospitals$xSecurity measures$xEvaluation.
615  0$aOpioid abuse
615  0$aDrugs$xPrescribing$xCorrupt practices
801  0$bGPO
801  1$bGPO
801  2$bGPO
801  2$bMERUC
801  2$bOCLCF
801  2$bINT
801  2$bGPO
906   $aBOOK
912   $a9910709638203321
996   $aAssessing VA's risks for drug diversion$93471003
997   $aUNINA